Age-Stratified Sirolimus Trough Concentrations in Pediatric Vascular Malformations: A Real-World Retrospective Study

BACKGROUND: Sirolimus is increasingly being used off-label to treat pediatric vascular malformations. In this study, the age-stratified drug exposure, pharmacokinetic variability, and long-term treatment characteristics of sirolimus were evaluated in a real-world pediatric population. METHODS: In this study, 144 patients (younger than 19 years) with vascular malformations who were treated with sirolimus at a single center (July 2018 and March 2025) were retrospectively analyzed. A total of 2054 therapeutic drug monitoring measurements were obtained. The patients were stratified into 6 age groups (1 month and younger to 12-18 years). The outcomes included trough concentration, interindividual variability (coefficient of variation), target range attainment, treatment duration, and MRI-based response. RESULTS: The median follow-up was 18.3 months (range, 0.3-74.1 months). Neonates (1 month and younger) showed the highest interindividual variability (coefficient of variation = 61.6%), with lower variability observed in adolescents (40.0%, P < 0.001). Overall, 73.4% of the trough concentrations were within the target range (4-10 ng/mL), and the mean duration within the therapeutic range per patient was 70.9%. Supratherapeutic levels (>15 ng/mL) were most frequent in neonates (6.6%). Prolonged therapy (≥24 months) was observed in 31.9% of patients, with a median duration of 35.1 months. Among the 44 patients who underwent follow-up MRI, 84.1% showed disease improvement or stability. CONCLUSIONS: Sustained long-term treatment continuity suggests that sirolimus was generally tolerated across pediatric age groups, although direct toxicity data were not systematically captured in this study. Younger patients exhibited greater pharmacokinetic variability, necessitating closer monitoring and cautious dose adjustment. Prospective PK-PD studies incorporating standardized clinical outcomes are needed to define optimal trough targets and individualized dosing strategies.

Authors

Institutions

Publication Details

Journal
Therapeutic Drug Monitoring
Published
2026-11-20
DOI
https://doi.org/10.1097/ftd.0000000000001554
Primary Topic
Vascular Malformations and Hemangiomas
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Age-Stratified Sirolimus Trough Concentrations in Pediatric Vascular Malformations: A Real-World Retrospective Study

Dae Yeon Kim, Yong Jae Kwon, Jung-Man Namgoong, Soo-Min Jung et al.
3 links
Therapeutic Drug Monitoring
Vascular Malformations and Hemangiomas
article

Age-Stratified Sirolimus Trough Concentrations in Pediatric Vascular Malformations: A Real-World Retrospective Study

Dae Yeon Kim, Yong Jae Kwon, Jung-Man Namgoong, Soo-Min Jung, Hyunhee Kwon, Suhyeon Ha
article en

Abstract

BACKGROUND: Sirolimus is increasingly being used off-label to treat pediatric vascular malformations. In this study, the age-stratified drug exposure, pharmacokinetic variability, and long-term treatment characteristics of sirolimus were evaluated in a real-world pediatric population. METHODS: In this study, 144 patients (younger than 19 years) with vascular malformations who were treated with sirolimus at a single center (July 2018 and March 2025) were retrospectively analyzed. A total of 2054 therapeutic drug monitoring measurements were obtained. The patients were stratified into 6 age groups (1 month and younger to 12-18 years). The outcomes included trough concentration, interindividual variability (coefficient of variation), target range attainment, treatment duration, and MRI-based response. RESULTS: The median follow-up was 18.3 months (range, 0.3-74.1 months). Neonates (1 month and younger) showed the highest interindividual variability (coefficient of variation = 61.6%), with lower variability observed in adolescents (40.0%, P < 0.001). Overall, 73.4% of the trough concentrations were within the target range (4-10 ng/mL), and the mean duration within the therapeutic range per patient was 70.9%. Supratherapeutic levels (>15 ng/mL) were most frequent in neonates (6.6%). Prolonged therapy (≥24 months) was observed in 31.9% of patients, with a median duration of 35.1 months. Among the 44 patients who underwent follow-up MRI, 84.1% showed disease improvement or stability. CONCLUSIONS: Sustained long-term treatment continuity suggests that sirolimus was generally tolerated across pediatric age groups, although direct toxicity data were not systematically captured in this study. Younger patients exhibited greater pharmacokinetic variability, necessitating closer monitoring and cautious dose adjustment. Prospective PK-PD studies incorporating standardized clinical outcomes are needed to define optimal trough targets and individualized dosing strategies.

Therapeutic Drug Monitoring
Asan Medical Center (KR), University of Ulsan (KR)
Good health and well-being
Vascular Malformations and Hemangiomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon